Reducing the dosage of bFGF minimizes the risks associated with high-dose treatments, such as thrombocytopenia, renal toxicity, and malignant cell activation [20,21], while still optimizing the regenerative effects of the therapy. This evidence concerns the gene FGF2 and Thrombocytopenia.